GURU.Markets stock price, segment price, and overall market index valuation
The company's share price COGT
Cogent Biosciences is a biotech company focused on treating rare genetic diseases. Its stock price is driven by news of clinical trials of its targeted drugs. The chart reflects investor confidence in the potential of its scientific platform.
Share prices of companies in the market segment - Specialized pharma
Cogent Biosciences is a biotech company developing drugs to treat rare genetic diseases. We classify it as a Specialized Pharma company, and the chart below reflects the dynamics of the entire industry, where a company's value is entirely dependent on the success of clinical trials.
Broad Market Index - GURU.Markets
Cogent Biosciences is an oncology company developing targeted therapies for genetically determined diseases such as systemic mastocytosis. It is a component of the GURU.Markets index. The chart below represents the market. See how Cogent shares compare to the biotech sector.
Change in the price of a company, segment, and market as a whole per day
COGT - Daily change in the company's share price COGT
Shares of Cogent Biosciences, a biopharmaceutical company, exhibit high volatility, measured by change_co. This indicator reflects sensitivity to news about clinical trials of its drugs. This metric is a key component of formulas on System.GURU.Markets for risk analysis in the biotech sector.
Daily change in the price of a set of shares in a market segment - Specialized pharma
Cogent Biosciences, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with COGT, which focuses on rare disease treatments, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Cogent Biosciences is a biopharmaceutical company specializing in drugs to treat genetic diseases. Biotechnology is a volatile sector. The chart below shows average daily fluctuations in this sector, providing context for analyzing Cogent's stock performance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization COGT
Cogent is a biotechnology company specializing in rare diseases. Its year-over-year performance reflects the commercial success of its drugs and investor confidence in its R&D platform, which is focused on new breakthrough medicines.
Annual dynamics of market capitalization of the market segment - Specialized pharma
Cogent Biosciences, Inc. is a clinical-stage biotechnology company developing targeted therapies for the treatment of rare genetic diseases. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Cogent Biosciences is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization COGT
The value of Cogent Biosciences, a biopharmaceutical company, is speculative. Monthly fluctuations on the chart reflect not revenue, but rather news about the progress of clinical trials of its drugs for treating rare genetic diseases, the success of which determines its entire future valuation.
Monthly dynamics of market capitalization of the market segment - Specialized pharma
Cogent Biosciences is a biotechnology company developing targeted drugs for the treatment of genetically determined diseases, including rare forms of cancer and mastocytosis. The chart below illustrates the overall dynamics in the precision medicine sector, where scientific breakthroughs can lead to the creation of highly effective drugs.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Cogent Biosciences is a clinical-stage biotech company. Without any commercial products, its shares are entirely dependent on research results and drug development news. Their performance is disconnected from overall market trends and reflects solely investor confidence in the company's scientific potential.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization COGT
Shares of Cogent Biosciences, a biotech company developing precision treatments for genetic diseases, reflect the high stakes of the pharmaceutical industry every week. Price movements reflect data from preclinical and clinical trials, where any result can lead to a rise or fall.
Weekly dynamics of market capitalization of the market segment - Specialized pharma
The precision oncology sector of biotech is a field where weekly performance is driven by scientific discoveries. Clinical trial data for targeted drugs influences sentiment across the entire niche. The chart provides this backdrop against which Cogent Biosciences' progress can be assessed.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Cogent Biosciences is a biotech company developing precision treatments for genetically determined diseases. Shares of such innovative companies often move independently of the market. This chart will help you understand: is Cogent living in its own world of clinical trials, or is the overall market environment influencing its stock price?
Market capitalization of the company, segment and market as a whole
COGT - Market capitalization of the company COGT
The market capitalization chart of Cogent Biosciences tells the story of a biotech company focused on developing targeted therapies for genetically determined diseases. Its volatile chart reflects the hopes and setbacks associated with clinical trials. Its dynamics reflect the market's assessment of the scientific potential of its drugs and the chances of their approval by regulators.
COGT - Share of the company's market capitalization COGT within the market segment - Specialized pharma
Cogent Biosciences is a biotechnology company developing targeted drugs for the treatment of genetically determined diseases, including rare cancers. Its market share currently reflects the potential of its developments. Its market capitalization is a bet on the success of its clinical trials and future medical breakthroughs.
Market capitalization of the market segment - Specialized pharma
Cogent Biosciences is a biotechnology company developing targeted therapies for rare genetic diseases. The chart below shows the overall market capitalization of this research-intensive sector. Its dynamics reflect investors' faith in scientific breakthroughs that can radically change patients' lives.
Market capitalization of all companies included in a broad market index - GURU.Markets
Cogent Biosciences is a biotech company developing targeted drugs for the treatment of genetically determined diseases, particularly rare tumors. Its market capitalization is driven by a bet on breakthroughs in precision medicine. The chart below shows the importance of this area.
Book value capitalization of the company, segment and market as a whole
COGT - Book value capitalization of the company COGT
Cogent Biosciences' book value is its capital dedicated to clinical research and the development of targeted drugs for rare genetic diseases. This is a tangible, scientific foundation aimed at precisely combating diseases. How has this innovative asset grown? The chart below shows its growth dynamics.
COGT - Share of the company's book capitalization COGT within the market segment - Specialized pharma
Cogent Biosciences is a biotechnology company developing targeted therapies, which requires its own or leased laboratories. The chart shows the share of these science-intensive tangible assets in the sector, reflecting the physical foundation of its research activities.
Market segment balance sheet capitalization - Specialized pharma
Biopharmaceuticals, as the BCap_Seg chart shows, are less capital-intensive than heavy industry but require significant investment in R&D. Cogent Biosciences operates in this environment, where its assets are not factories, but laboratories and intellectual property for drugs for rare diseases.
Book value of all companies included in the broad market index - GURU.Markets
Cogent Biosciences' book value is derived not from its factories, but from its cutting-edge research laboratories and accumulated intellectual property. Although these assets are intangible, their value reflects the capital invested in developing potential drugs that could have a profound impact on the real world of healthcare.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - COGT
Cogent Biosciences is a clinical-stage biotech company. Its book value is primarily cash on hand. Its market capitalization is a bet on the success of its experimental drugs. The MvsBCap chart is extremely volatile and reflects investor expectations of trial results, not the value of its actual assets.
Market to book capitalization ratio in a market segment - Specialized pharma
Cogent Biosciences is a biotech company focused on treating genetically determined diseases. Its value is determined almost entirely by the potential of its scientific developments and patents. This chart shows how investors value its scientific portfolio compared to its virtually nonexistent tangible assets.
Market to book capitalization ratio for the market as a whole
Cogent Biosciences is a biotech company focused on developing precision therapies for genetically determined diseases. Its value is made up almost entirely of intangible assets: research, patents, and the potential for future drugs. The chart shows how investors value the science and hope that have not yet been converted into revenue.
Debts of the company, segment and market as a whole
COGT - Company debts COGT
Cogent Biosciences, a clinical-stage biopharmaceutical company, uses raised capital to fund the research and development of its targeted therapies. Until a product is brought to market, the company has no revenue and is entirely dependent on external funding. This chart illustrates how the company manages its resources on the path to developing new drugs.
Market segment debts - Specialized pharma
Cogent Biosciences is a biotechnology company focused on developing precision treatments for genetic diseases. For companies in clinical development, debt is critical to funding R&D before bringing a product to market. This chart illustrates how Cogent manages capital on its path to commercialization.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio COGT
Cogent Biosciences is a biotech company focused on treating genetically determined diseases. The chart shows how it finances its research. For a development-stage biopharma with no stable revenue, debt is a risky instrument. Its presence and size reflect the lenders' confidence in the success of the company's future drugs.
Market segment debt to market segment book capitalization - Specialized pharma
Cogent Biosciences is a clinical-stage biotech company, meaning it has high R&D costs and no revenue. This chart, for the pharmaceutical industry, illustrates how the sector as a whole funds lengthy and expensive research. It helps assess how typical the company's financial position is for the risky world of biotech.
Debt to book value of all companies in the market
Cogent Biosciences is a biotech company whose funding depends on investor confidence in its future drugs. This chart reflects the overall risk appetite in the economy. For a company without revenue, it helps understand how its debt- or equity-based financing model compares to the overall market.
P/E of the company, segment and market as a whole
P/E - COGT
For Cogent Biosciences, a biotech company in drug development, this chart is often uninformative or extremely high. It reflects not current profits, but rather investors' hopes for the success of clinical trials and the future commercial potential of its drugs for rare diseases.
P/E of the market segment - Specialized pharma
This chart shows the average price-to-earnings ratio for the biotech sector in which Cogent Biosciences operates. The industry is valued not by current earnings, but by future potential. The chart shows the overall level of optimism in the sector, providing context for assessing the risks and expectations embedded in Cogent's price.
P/E of the market as a whole
Cogent Biosciences is a biotech company focused on developing targeted therapies for the treatment of genetic diseases. It's a high-risk, but potentially high-reward business. This chart of overall market risk appetite helps us understand whether investors are willing to bet on Cogent's long-term scientific breakthroughs or prefer safer assets.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company COGT
Cogent Biosciences is a biotechnology company developing targeted therapies for the treatment of genetically determined diseases. The chart reflects investors' speculative expectations for future revenue, which are entirely dependent on the success of clinical trials and subsequent drug approval. This is a bet on a scientific breakthrough.
%20P%2FE%20COGT&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-COGT&v=1772531473281 "Chart of the company's future (projected) P/E COGT")
Future (projected) P/E of the market segment - Specialized pharma
Cogent Biosciences is a biotech company developing targeted therapies for genetically determined diseases. Its value depends on the success of clinical trials. This chart compares Cogent's future profitability expectations with those of the industry. It helps us understand how optimistic the market is about its scientific developments.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Specialized-pharma&v=1772531473327 "Future (projected) P/E graph of the market segment - Specialized pharma")
Future (projected) P/E of the market as a whole
Cogent Biosciences is a biotech company focused on developing precision treatments for genetically determined diseases. Its value is based on the potential of its scientific developments. This overall risk appetite chart shows how willing investors are to fund long-term, risky biotech projects in anticipation of future breakthroughs.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772531473378 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit COGT
Cogent Biosciences is a clinical-stage biotechnology company focused on developing drugs for the treatment of genetic diseases. Its financial metrics currently reflect research and development (R&D) expenses. This chart shows the amount of R&D investment that could lead to significant future profits if the drugs are approved.
Profit of companies in the market segment - Specialized pharma
Cogent Biosciences is a biotech company focused on developing precision treatments for genetically determined diseases. Its value is determined by progress in clinical trials. This chart illustrates the overall picture in the specialty pharmaceutical sector, where high R&D risks can lead to either failure or a blockbuster.
Overall market profit
Cogent Biosciences is a biotechnology company focused on developing precision treatments for genetically determined diseases. Its value and prospects are determined by clinical trial results, not short-term economic cycles. The dynamics in this chart have virtually no impact on the scientific progress and potential of Cogent's drugs.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company COGT
Cogent Biosciences is a biotechnology company focused on developing precision treatments for genetically determined diseases. Its future profitability is entirely dependent on the success of clinical trials and regulatory approvals. This chart reflects analysts' speculative expectations regarding the scientific and commercial potential of Cogent's developments.
%20profit%20of%20the%20company%20COGT&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-COGT&v=1772531473523 "Graph of future (projected) profit of the company COGT")
Future (predicted) profit of companies in the market segment - Specialized pharma
Cogent Biosciences is a biotechnology company focused on developing precision treatments for genetically determined diseases, particularly systemic mastocytosis. Its future depends on the success of clinical trials. This chart shows overall revenue projections for the pharmaceutical sector, providing context for assessing the potential of this highly specialized company.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Specialized-pharma&v=1772531473582 "Graph of future (predicted) profits of companies in a market segment - Specialized pharma")
Future (predicted) profit of the market as a whole
Cogent Biosciences is a biotechnology company developing precision treatments for genetic diseases. Its success depends on clinical trial results and funding. The overall economic environment, reflected in this chart, influences investors' risk appetite and their willingness to invest in the biotechnology sector.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772531473657 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - COGT
Cogent Biosciences is a clinical-stage biotech company developing targeted therapies. Revenue may not be available at this stage. The chart will reflect investors' confidence in the scientific platform and the potential commercial success of future drugs. Any movement on the chart is a reaction to research news, not current sales.
P/S market segment - Specialized pharma
Cogent Biosciences is a biotechnology company developing precision treatments for genetically determined diseases, particularly rare forms of cancer and systemic mastocytosis. Their focus on targeted therapies is opening new horizons in medicine. This chart shows the average revenue estimate in the pharmaceutical sector, reflecting investor expectations for Cogent's innovations.
P/S of the market as a whole
Cogent Biosciences is a biotech company developing precision treatments for genetically determined diseases. The company is in clinical trials. This chart, showing average revenue estimates, highlights that traditional metrics don't work for these companies, and their valuation is based solely on faith in the future success of their drugs.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company COGT
Cogent Biosciences is a biotechnology company focused on developing targeted therapies for the treatment of genetically determined diseases. For a company in the clinical trial stage, future revenue estimates are hypothetical but crucial. They reflect investors' confidence in the scientific potential of its drugs and the likelihood of their future commercial success after approval.
%20P%2FS%20COGT&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-COGT&v=1772531473869 "The graph of the company's future (projected) P/S COGT")
Future (projected) P/S of the market segment - Specialized pharma
Cogent Biosciences is a biotechnology company developing targeted therapies for genetically determined diseases, including rare cancers. This chart compares the company's estimated future sales with industry expectations. It reflects investor confidence in the company's scientific potential and its ability to successfully complete clinical trials and bring its drugs to market.
%20P%2FS%20market%20segment%20graph%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Specialized-pharma&v=1772531473895 "Future (projected) P/S market segment graph - Specialized pharma")
Future (projected) P/S of the market as a whole
Cogent Biosciences develops targeted therapies for genetically determined diseases. The company's activities are at the cutting edge of science, and its potential doesn't always correlate with current economic cycles. It represents innovative biotechnology that influences future forecasts, as reflected in the chart.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772531473913 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales COGT
This chart shows the revenue of Cogent Biosciences, a biotechnology company developing precision treatments for genetically determined diseases. Because the company is in clinical trials, its revenue may come from grants or partnerships rather than sales. The trend reflects progress in research and funding.
Sales of companies in the market segment - Specialized pharma
Cogent Biosciences is a biotechnology company focused on developing targeted therapies for the treatment of genetically determined diseases. As the company is in the development stage, its revenue may come from royalties or grants. The future sales mix will determine which of its drug candidates will become commercially successful.
Overall market sales
Cogent Biosciences is a biotechnology company focused on developing precision treatments for genetically determined diseases. Its success depends on clinical trial results and scientific breakthroughs, not on the current economic climate. This chart helps us understand how an innovation-driven sector coexists with the traditional economy.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company COGT
Cogent Biosciences is a biotechnology company focused on developing targeted therapies for the treatment of genetically determined diseases, particularly systemic mastocytosis. Future revenue depends on the success of clinical trials and the commercialization of its drugs. This chart reflects analysts' expectations for potential sales if the drugs are approved.
%20sales%20of%20the%20company%20COGT&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-COGT&v=1772531474124 "Schedule of future (projected) sales of the company COGT")
Future (projected) sales of companies in the market segment - Specialized pharma
Cogent Biosciences is a biotechnology company focused on developing precision treatments for genetically determined diseases. This chart shows sales forecasts for the specialty pharmaceuticals segment. Is market growth expected due to new discoveries? This allows us to assess the overall scientific and commercial potential of the industry.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Specialized-pharma&v=1772531474158 "Schedule of future (projected) sales of companies in the market segment - Specialized pharma")
Future (projected) sales of the market as a whole
Cogent Biosciences is a biotechnology company developing drugs to treat genetically determined diseases. Its success depends on clinical trial results, regulatory approvals, and scientific progress, not on general economic cycles. This chart, which shows consumer spending, has virtually no impact on the company's operations or prospects.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772531474221 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality COGT
Cogent Biosciences is a biotechnology company developing precision treatments for genetically determined diseases. This chart reflects its financial performance at the clinical trial stage. Profitability is a future goal, while current indicators demonstrate the level of investment in research that could lead to the development of breakthrough drugs.
Market segment marginality - Specialized pharma
Cogent Biosciences is a clinical-stage biotechnology company developing drugs to treat genetically determined diseases. Currently, the company is investing heavily in research and clinical trials. This chart reflects its current financial performance, with profitability dependent on the future approval and commercialization of its drugs.
Market marginality as a whole
Cogent Biosciences is a biotechnology company developing precision treatments for genetically determined diseases. Its success depends on long-term investment in research. This total return chart reflects investors' risk appetite: during periods of economic growth, they are more willing to fund innovative but risky projects.
Employees in the company, segment and market as a whole
Number of employees in the company COGT
Cogent Biosciences is a biotechnology company developing drugs to treat genetically determined diseases. Its small but highly qualified staff consists of scientists and researchers. This graph reflects the development phase: the team's growth indicates that the drugs are advancing through clinical trials, which requires the addition of new specialists.
Share of the company's employees COGT within the market segment - Specialized pharma
Cogent Biosciences is a biotechnology company focused on developing precision treatments for genetically determined diseases. Its staff consists primarily of scientists, researchers, and clinicians. This chart shows the company's labor market share in a narrow pharmaceutical niche, reflecting its focus on R&D and its ability to attract highly specialized scientific talent.
Number of employees in the market segment - Specialized pharma
Cogent Biosciences is a biotechnology company focused on developing precision treatments for genetically determined diseases. The chart shows employment in specialized pharmaceuticals. The growing number of scientists in this field reflects breakthroughs in genomics and the high investment interest in targeted therapies, which are at the core of Cogent's strategy.
Number of employees in the market as a whole
Cogent Biosciences is a biotechnology company developing targeted therapies for the treatment of genetic diseases. Its staff consists of scientists and researchers. The team's growth, compared to the overall employment in this chart, speaks not to the state of the economy, but to progress in science and the attraction of investment in promising clinical developments.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company COGT (COGT)
Cogent Biosciences is a biotech company. This chart shows how the market values their scientific potential. Their entire value can be captured in a single promising development created by a small team. The market capitalization per employee can be extremely high, reflecting not current sales but investor expectations for a future breakthrough.
%20of%20the%20company%20COGT%20(COGT)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-COGT-COGT&v=1772531474623 "Chart of market capitalization per employee (in thousands of dollars) of the company COGT (COGT)")
Market capitalization per employee (in thousands of dollars) in the market segment - Specialized pharma
Cogent Biosciences (COGT) is a biotech company developing targeted therapies for rare genetic diseases, specifically systemic mastocytosis. It is an R&D-focused business. This chart shows the average market capitalization per employee in the sector. It helps assess how the market values their scientific platform and R&D portfolio per scientist.
%20by%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Specialized-pharma&v=1772531474654 "Market capitalization per employee (in thousands of dollars) by market segment - Specialized pharma")
Market capitalization per employee (in thousands of dollars) for the overall market
Cogent Biosciences is a biotech company developing drugs to treat genetically determined diseases. At this stage, its value is determined not by sales, but by the potential of its scientific developments. The chart shows a high valuation per employee, as the market factors in the future success of clinical trials and patents.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772531474738 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company COGT (COGT)
Cogent Biosciences is a clinical-stage biotech company developing precision treatments for rare diseases. This chart likely shows a loss per employee. This is typical for biotech: the company invests in R&D, and each scientist "burns" capital for the sake of a future breakthrough. This metric reflects the investment phase.
%20Chart%20COGT%20(COGT)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-COGT-COGT&v=1772531474778 "Company Profit Per Employee (in thousands of dollars) Chart COGT (COGT)")
Profit per employee (in thousands of dollars) in the market segment - Specialized pharma
Cogent Bio (COGT) is an R&D biotech company (oncology, rare diseases). This chart shows the benchmark for "Specialty Pharma" (R&D). The average profit per employee in this sector (venture R&D) is *negative*. This benchmark reflects the "burning" of cash in the hopes of one or two mega-successes. The entire sector is an R&D race.
%20in%20the%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Specialized-pharma&v=1772531474815 "Chart of profit per employee (in thousands of dollars) in the market segment - Specialized pharma")
Profit per employee (in thousands of dollars) for the market as a whole
Cogent Biosciences is a clinical-stage biotech company specializing in rare diseases and oncology. Like other R&D biopharmaceuticals, they are not profitable. This chart shows the operating loss per employee—the "burn rate" of capital spent on breakthrough research and clinical trials.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772531474835 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee COGT (COGT)
Cogent Biosciences is a biotech company in the drug development stage. In the early stages, revenue per employee may be low or nonexistent. However, if the company is successful and the product reaches market, this metric will skyrocket, reflecting the enormous value of the intellectual property generated by a small team of scientists.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-COGT-COGT&v=1772531474860 "Sales chart per company employee COGT (COGT)")
Sales per employee in the market segment - Specialized pharma
Cogent Biosciences is a biotech company working on targeted therapies (precision medicine), primarily in oncology. It's purely R&D. Revenue (if any) often comes from partners or grants. This chart shows the average revenue for the sector. For Cogent, which is in the research stage, this is more of a leading indicator: how do their personnel costs compare to their success?
Sales per employee for the market as a whole
Cogent Biosciences is a biotech company developing targeted therapies. During the clinical trials phase, the company generates little or no revenue. This indicator will only be meaningful after the drug is commercialized. It will demonstrate the effectiveness of their sales model for their relatively small R&D and G&A team.
Short shares by company, segment and market as a whole
Shares shorted by company COGT (COGT)
Cogent Biosciences (COGT) is a clinical-stage biotech developing targeted therapies for rare diseases. This chart shows the number of short positions. Like many biotechs without revenue, the high short position reflects bets that their key drug candidate will fail clinical trials or underperform competitors.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-COGT-COGT&v=1772531474974 "Short Shares Chart for the Company COGT (COGT)")
Shares shorted by market segment - Specialized pharma
Cogent Biosciences (COGT) is a biotech company developing precision treatments for genetically determined diseases, particularly rare forms of cancer. This chart aggregates short positions across the entire biotech sector. It reflects general investor skepticism about the risks of clinical trials or concerns about funding.
Shares shorted by the overall market
Cogent Biosciences (COGT) is a clinical-stage biotech (oncology). This indicator (`Short_All`) is a mirror of market fear. When it rises, investors panic and dump risk, especially unprofitable biotechs. This pessimism, visible on the chart, deprives COGT of access to the capital needed for expensive trials.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator COGT (COGT)
Cogent Biosciences is a clinical-stage biotech company. Its shares are highly sensitive to trial news. This chart for COGT can surge above 70 on positive R&D data. Oversold territory (<30) often reflects research setbacks or a general aversion to risk in biotech.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-COGT-COGT&v=1772531475069 "RSI 14 indicator chart for the company's stock COGT (COGT)")
RSI 14 Market Segment - Specialized pharma
Cogent Biosciences (COGT) is a biotech company developing precision inhibitors for the treatment of rare genetic diseases and cancer. The RSI_14_Seg for "Specialized Pharma" reflects the overall sentiment in the biotech sector. The chart helps us understand: is COGT's volatility a reaction to its trials or general hype?
RSI 14 for the overall market
Cogent Biosciences (COGT) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast COGT (COGT)
Cogent Biosciences is a clinical-stage biotechnology company developing targeted therapies (inhibitors) for the treatment of rare genetic diseases and cancer. This chart represents analyst consensus. Their target prices are based entirely on estimates of the likelihood of clinical trial success and the market potential of their drug candidates.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-COGT-COGT&v=1772531475179 "A chart showing analyst consensus forecasts for the expected stock price. COGT (COGT)")
The difference between the consensus estimate and the actual stock price COGT (COGT)
Cogent Biosciences is a clinical-stage biotech company developing precision-targeted therapies for rare genetic diseases, primarily systemic mastocytosis. This chart reflects analysts' speculative expectations regarding their clinical data and the potential of their lead drug.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-COGT-COGT&v=1772531475229 "A chart showing the difference between the consensus forecast and the actual stock price. COGT (COGT)")
Analyst consensus forecast for stock prices by market segment - Specialized pharma
Cogent Biosciences is a biotech company developing targeted therapies for genetically determined diseases, such as systemic mastocytosis. This chart shows analysts' overall expectations for the specialty pharmaceuticals sector. It reflects whether experts believe in the commercial potential of their lead drug candidate.
Analysts' consensus forecast for the overall market share price
Cogent Biosciences is a biotech company focused on treating rare genetic diseases such as systemic mastocytosis. This is precision medicine. This chart shows overall market sentiment. For Cogent, as an R&D-stage biotech, it's important to understand how overall risk appetite (analyst sentiment) influences funding for their expensive research. (349)
AKIMA index of the company, segment and market as a whole
AKiMA Company Index COGT
Cogent Biosciences (COGT) is a clinical-stage biotech focused on precision therapies—developing drugs against specific genetic mutations that cause cancer and rare diseases. This chart represents a high-risk R&D bet. Its valuation is not tied to revenue but rather reflects investor confidence in their scientific platform and clinical trial data.
AKIMA Market Segment Index - Specialized pharma
Cogent Biosciences (COGT) is a clinical-stage biotech focused on rare diseases; the company is developing targeted drugs (KIT inhibitors) for the treatment of systemic mastocytosis (SM). This summary metric evaluates R&D. The graph shows the segment average. This is a benchmark: how does COGT's ultra-niche (SM) R&D focus differentiate it from the average pharma company?
The AKIM Index for the overall market
Cogent Biosciences is a biotech company developing precision treatments for genetically determined diseases (systemic mastocytosis). This chart, reflecting the market average, provides a macro backdrop. It helps assess how this speculative scientific story, fueled by trial data, compares to overall economic trends that influence risk appetite.
